We are live on
!
Find out more
EC
EcoR1 Capital Portfolio holdings
AUM
$2.34B
1-Year Est. Return
204.53%
This Fund
S&P 500
This Quarter
Est. Return
+43.68%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$1.34B
AUM Growth
+$378M
(+40%)
Cap. Flow
+$106M
Cap. Flow
% of AUM
7.93%
Top 10 Holdings %
Top 10 Hldgs %
61.12%
Holding
70
New
18
Increased
13
Reduced
7
Closed
23
Top Buys
| 1 |
Oric Pharmaceuticals
ORIC
|
+$84.3M |
| 2 |
Xencor
XNCR
|
+$62.7M |
| 3 |
RNAM
Avidity Biosciences
RNAM
|
+$60.7M |
| 4 |
AKUS
Akouos Inc
AKUS
|
+$44M |
| 5 |
Arcus Biosciences
RCUS
|
+$41M |
Top Sells
| 1 |
Arvinas
ARVN
|
+$61.6M |
| 2 |
Fate Therapeutics
FATE
|
+$51.3M |
| 3 |
Ironwood Pharmaceuticals
IRWD
|
+$45M |
| 4 |
KYNB
Kyntra Bio
KYNB
|
+$30.7M |
| 5 |
IPHA
Innate Pharma
IPHA
|
+$29.8M |
Sector Composition
| 1 | Healthcare | 93.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Xencor
XNCR
$1.11B
| $147M | 11.03% |
4,547,072
+2,045,515
| +82% | +$62.7M |
|
2
Prothena Corp
PRTA
$446M
| $98.6M | 7.38% |
9,426,640
| – | – |
|
|
3
Oric Pharmaceuticals
ORIC
$1.11B
| $89.1M | 6.67% |
+2,642,218
| New | +$84.3M |
|
|
MORF
4
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $76.8M | 5.75% |
2,837,973
+14,832
| +0.5% | +$278K |
|
5
Kura Oncology
KURA
$999M
| $75.1M | 5.62% |
4,608,529
+1,096,839
| +31% | +$15.8M |
|
6
Assembly Biosciences
ASMB
$531M
| $73.5M | 5.51% |
262,816
+46,926
| +22% | +$10.9M |
|
|
DRNA
7
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $69.1M | 5.18% |
2,721,993
-624,308
| -19% | -$13.4M |
|
8
AnaptysBio
ANAB
$1.68B
| $68.7M | 5.14% |
3,075,014
+39,000
| +1% | +$713K |
|
|
RNAM
9
DELISTED
Avidity Biosciences
RNAM
| $59.5M | 4.45% |
+2,103,950
| New | +$60.7M |
|
10
Neurogene
NGNE
$776M
| $58.7M | 4.4% |
176,834
-7,826
| -4% | -$2.04M |
|
|
11
Arcus Biosciences
RCUS
$3.52B
| $44.8M | 3.35% |
1,810,000
+1,517,900
| +520% | +$41M |
|
|
AKUS
12
DELISTED
Akouos Inc
AKUS
| $44.5M | 3.33% |
+1,975,984
| New | +$44M |
|
13
Geron
GERN
$905M
| $41.9M | 3.14% |
+19,230,769
| New | +$28.7M |
|
|
MRTX
14
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $40.9M | 3.06% |
357,849
| – | – |
|
15
Ultragenyx Pharmaceutical
RARE
$3.12B
| $40.6M | 3.04% |
519,119
+147,911
| +40% | +$9.79M |
|
|
SURF
16
DELISTED
Surface Oncology, Inc. Common Stock
SURF
| $33M | 2.47% |
5,033,861
+3,759,398
| +295% | +$13.6M |
|
|
BCEL
17
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
| $31.7M | 2.37% |
1,489,185
+383,005
| +35% | +$6.77M |
|
|
AMTI
18
DELISTED
Applied Molecular Transport Inc. Common Stock
AMTI
| $28.9M | 2.16% |
+1,150,000
| New | +$29M |
|
|
CNST
19
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $25.2M | 1.89% |
+837,885
| New | +$30.2M |
|
|
20
Fate Therapeutics
FATE
$345M
| $21.3M | 1.59% |
619,855
-1,722,020
| -74% | -$51.3M |
|
21
Denali Therapeutics
DNLI
$3.63B
| $17.7M | 1.33% |
733,561
+35,460
| +5% | +$834K |
|
|
BMY.RT
22
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
| $17M | 1.27% |
4,748,300
+2,500,000
| +111% | +$9.02M |
|
23
Cyclerion Therapeutics
CYCN
$16.3M
| $16.2M | 1.21% |
137,114
| – | – |
|
24
Fulcrum Therapeutics
FULC
$237M
| $16.1M | 1.21% |
+882,353
| New | +$13.9M |
|
25
Crinetics Pharmaceuticals
CRNX
$8.88B
| $15.1M | 1.13% |
859,802
+509,802
| +146% | +$8.69M |
|
Similar funds
G
MC
BAM
CC
HFM
NO
ST
MFAM